

A service of the National Library of Medicine  
and the National Institutes of Health

My NCBI

[\[Sign In\]](#) [\[Register\]](#)

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books  
Search  for    Save Search

Limits Preview/Index History Clipboard Details  
Display  Show  Sort by  Send to

All: 2 Review: 0

Items 1 - 2 of 2

One page.

1: [Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ; C-SIRIUS Investigators.](#) Related Articles, Links  
The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS).

J Am Coll Cardiol. 2004 Mar 17;43(6):1110-5.  
PMID: 15028375 [PubMed - indexed for MEDLINE]

2: [Humphreys WG, Obermeier MT, Morrison RA.](#) Related Articles, Links  
Continuous blood withdrawal as a rapid screening method for determining clearance of oral bioavailability in rats.

Pharm Res. 1998 Aug;15(8):1257-61.  
PMID: 9706058 [PubMed - indexed for MEDLINE]

[About Entrez](#)  
[NCBI Toolbar](#)

[Text Version](#)

[Entrez PubMed](#)  
[Overview](#)  
[Help | FAQ](#)  
[Tutorials](#)  
[New/Noteworthy](#)  
[E-Utilities](#)

[PubMed Services](#)  
[Journals Database](#)  
[MeSH Database](#)  
[Single Citation](#)  
[Matcher](#)  
[Batch Citation](#)  
[Matcher](#)  
[Clinical Queries](#)  
[Special Queries](#)  
[LinkOut](#)  
[My NCBI](#)

[Related](#)  
[Resources](#)  
[Order Documents](#)  
[NLM Mobile](#)  
[NLM Catalog](#)  
[NLM Gateway](#)  
[TOXNET](#)  
[Consumer Health](#)  
[Clinical Alerts](#)  
[ClinicalTrials.gov](#)  
[PubMed Central](#)

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
1	3	BMS-A	USPAT	OR	OFF	2006/02/27 19:31



BMS-A KINASE

Search

[Advanced Scholar Search](#)  
[Scholar Preferences](#)  
[Scholar Help](#)

Scholar

Results 1 - 10 of about 23 for **BMS-A KINASE**. (0.07 seconds)[Genetic Evidence That Protease-activated Receptors Mediate Factor Xa Signaling in Endothelial Cells - group of 4 »](#)

E Camerer, H Kataoka, M Kahn, K Lease, SR Coughlin - *J Biol Chem*, 2002 - [jbc.org](#)  
... using antibodies to phosphorylated (pERK) or total (ERK) MAP kinase as indicated. ... nM), AYPGKF (500 μM), TFLLRNPNDK (100 μM). BMS200261 (BMS, a PAR1 antagonist ...

[Cited by 49 - Web Search - BL Direct](#)[Drug Eluting Stents](#)YL Lee, J Lee - [jhu.edu](#)

... A hollow tube with slots mounted on a balloon catheter in a "crimped" or ... Inhibits mTOR, a downstream protein kinase of the phosphatidylinositol ...

[View as HTML - Web Search](#)[Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin ... - group of 4 »](#)

RS Herbst, M Arquette, DM Shin, K Dicke, EE Vokes, ... - *J Clin Oncol*, 2005 - [jco.org](#)  
... was not associated with a change in EGFR or phosphorylated extracellular signal-regulated kinase expression in 10 ... Merrill S. Kies, ImClone (A), BMS (A), BMS ( ...

[Cited by 2 - Web Search](#)[Intracellular trafficking by Star regulates cleavage of the Drosophila EGF receptor ligand Spitz - group of 8 »](#)

R Tsruya, A Schlesinger, A Reich, L Gabay, A Sapir ... - *GENES AND DEVELOPMENT*, 2002 - [genesdev.org](#)

... induction of target genes and the accumulation of activated MAP kinase (dpERK) (Schweitzer ... (A) The capacity of Star constructs to promote mSpi cleavage in S2 ...

[Cited by 28 - Web Search - BL Direct](#)[Early assessment of patients with suspected acute myocardial infarction by biochemical monitoring ... - group of 5 »](#)

J Ellenius, T Groth, B Lindahl, L Wallentin - *Clin Chem*, 1997 - [clinchem.org](#)

... Fax +46 18-531202; e-mail [Johan.Ellenius{at}BMSA.uu.se](mailto:Johan.Ellenius@BMSA.uu.se). ... Blood samples for measurement

of myoglobin, creatine kinase isoform MB, and troponin T were obtained ...

[Cited by 6 - Web Search - BL Direct](#)[Early and mid-term results of drug-eluting stent implantation in unprotected left main - group of](#)

[10 »](#)

A Chieffo, G Stankovic, E Bonizzoni, E Tsagalou, I ... - *Circulation*, 2005 - [circ.ahajournals.org](http://circ.ahajournals.org)

... A randomized study comparing surgery appears justified at present. ... Non-Q-wave MI was defined as elevation of total creatine **kinase** 2 times above the upper ...

[Cited by 12](#) - [Web Search](#)

[核因子-κB 活化在急性肺损伤发病中的作用 - group of 2 »](#)

郭振辉，洪新，毛宝龄，钱桂生，... - *中华急诊医学杂志*, 2003 - [维普资讯](#)

... B与B的结合特性、通过核蛋白中NF-~zB与标记的 . cB系列结合后的BMSA自显影结果，

反映了 ... JD , Gao X , Can E , et 81 . It~B kinase—8 NF ...

[Cited by 2](#) - [Web Search](#)

[Interventional Cardiology - group of 2 »](#)

A Chieffo, G Stankovic, E Bonizzoni, E Tsagalou, I ... - [summerinseattle.com](http://summerinseattle.com)

... A randomized study comparing surgery appears justified at present. ... Non-Q-wave MI was defined as elevation of total creatine **kinase** 2 times above the upper ...

[View as HTML](#) - [Web Search](#)

[Related Links - group of 2 »](#)

NG Avery, JL Kaiser, DM Barnes, MJ Sharman, TP ... - *The Journal of Strength and Conditioning Research* - [nsca.allenpress.com](http://nsca.allenpress.com)

... Key Words: lipid peroxidation, malondialdehyde, creatine **kinase**, delayed-onset muscle soreness ... A position transducer (Celesco, model PT 9510, Canoga Park, CA ...

[Web Search](#)

[Prospective Native Coronary Artery Stenosis Treated with Sirolimus-Eluting Stent \(ONASSIS\) Registry ... - group of 6 »](#)

V Voudris, E Alexopoulos, P Karyofillis, J Malakos ... - *J Invasive Cardiol*, 2005 - [hmpcommunications.com](http://hmpcommunications.com)

... procedure was defined as muscle-brain fraction of creatine **kinase** elevation > 3 ... A lower percentage of patients treated with SES received peri-procedural GP IIb ...

[Cached](#) - [Web Search](#)

Google ►

Result Page: [1](#) [2](#) [3](#) [Next](#)

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623SQS

**PASSWORD :**

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available  
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE  
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of  
TOXCENTER  
NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes  
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS  
with the  
NEWS 8 DEC 23 IPC reform  
USPATFULL/  
New IPC8 SEARCH, DISPLAY, and SELECT fields in  
USPAT2  
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB  
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements  
added to  
INPADOC  
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV  
NEWS 13 JAN 30 Saved answer limit increased  
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency  
added to TULSA  
NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN  
AnaVist  
visualization results  
NEWS 16 FEB 22 Status of current WO (PCT) information on STN  
NEWS 17 FEB 22 The IPC thesaurus added to additional patent  
databases on STN  
NEWS 18 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a

AT

<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 20:23:45 ON 27 FEB 2006

=> File Medline EMBASE Biosis Caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
SESSION  
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 20:23:56 ON 27 FEB 2006

FILE 'EMBASE' ENTERED AT 20:23:56 ON 27 FEB 2006  
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 20:23:56 ON 27 FEB 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 20:23:56 ON 27 FEB 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s EphA2 (4A) expression  
L1 208 EPHA2 (4A) EXPRESSION

=> s Kinase (3A) inhibitor  
L2 163473 KINASE (3A) INHIBITOR

=> s 11 and 12  
T-3 8 T-1 AND T-2

```
=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?) :remove
ENTER L# LIST OR (END) :13
```

DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, BIOSIS, CAPLUS'  
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L3

L4 5 DUPLICATE REMOVE L3 (3 DUPLICATES REMOVED)

=> d 14 1-5 bib ab

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:161005 CAPLUS

DN 142:254576

TI Inhibitors of EphA2, PCDGF, and HAAH for combination therapy and diagnosis

of prevention of hyperproliferative disorder, cancer and metastasis

IN Kinch, Michael S.; Carles-Kinch, Kelly; Kiener, Peter; Langermann,

Solomon; McCarthy, Michael P.; Tice, David; Woessner, Richard

PA Medimmune, Inc., USA

SO PCT Int. Appl., 177 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.
DATE				

PI WO 2005016381 A2 20050224 WO 2004-US23097  
20040716

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,  
SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,  
ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,  
DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT,  
RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
MR, NE,  
SN, TD, TG

PRAI US 2003-489036P P 20030721

AB The present invention relates to methods and compns. designed for the

treatment, management, or prevention of a hyperproliferative disorder,

particularly cancer, more particularly metastatic cancer. The methods of

the invention comprise the administration of an effective amount of one or

more agents that decrease/inhibit **EphA2** receptor tyrosine kinase (**EphA2**) **expression** or activity in combination with one or more agents that decrease/inhibit PC cell derived growth factor (PCDGF)

or human aspartyl (asparaginyl)  $\beta$ -hydroxylase (HAAH) expression or

activity. In another embodiment, the methods of the invention comprise

the administration of an effective amount of one or more EphA2, PCDGF,

and/or HAAH agents of the invention that inhibit cancer cell colony

formation in soft agar or tubular network formation in three-dimensional

basement membrane or extracellular matrix preparation. The invention also

provides pharmaceutical compns. comprising one or more EphA2 agents of the

invention in combination with one or more PCDGF agents of the invention

and/or one or more HAAH agents of the invention. In some embodiments, the

agents of the invention can be administered with other cancer therapeutic

agents that are not EphA2-, PCDGF-, or HAAH-based. Diagnostic methods and

methods for screening for therapeutically useful agents of the invention

are also provided.

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1020555 CAPLUS

DN 143:320266

TI Genes with differential expression profile between human dental pulp stem

cells and mesenchymal stem cells and use for regenerating tooth germ

IN Ueda, Minoru; Yamada, Yoichi

PA Hitachi Medical Corp., Japan

SO Jpn. Kokai Tokkyo Koho, 246 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.

KIND DATE

APPLICATION NO.

DATE

-----  
-----  
PI JP 2005253442  
20040309

A2 20050922

JP 2004-111582

PRAI JP 2004-111582

20040309

AB The present invention relates to a group of genes whose expression profile

are different between human dental pulp stem cells and mesenchymal stem

cells, as well as a method for regenerating tooth germ using these genes.

According to the present invention, the gene expression profiles and

cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cell were revealed, and a group of

genes whose expression profile are different between human dental pulp

stem cells and mesenchymal stem cells was identified. By utilizing the

groups of the genes of the present invention together with the dental pulp

stem cells and mesenchymal stem cells, hard tissue such as tooth germ,

dental pulp, dentin or bone can be regenerated. The present inventors

investigated the gene expression profiles and cluster anal. between human

dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as

representative populations of odontoprogenitor and osteoprogenitor cells,

resp. At first, the present inventors confirmed the differential expression of Alkaline phosphatase (ALP) activity, Dentin matrix protein 1

(DMP 1), Dentin phosphosialoprotein (DSPP) using by real time reverse-transcriptase polymerase chain reaction (RT-PCR) in total RNA from

primary cultures. The number of genes in hDPSCs(I) that were up-regulated by

2>-fold, compared to hMSCs, was 614 (Table, IV). On the other band, the

number of genes down regulated by <2-fold in hDPSCs (I) was 296 (Table III, IV).

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1097554 CAPLUS

DN 144:168423

TI Strong expression of ID1 protein is associated with decreased survival,

increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma

AU Straume, O.; Akslen, L. A.

CS The Gade Institute, Section for Pathology, University of Bergen, Bergen,

Norway

SO British Journal of Cancer (2005), 93(8), 933-938

CODEN: BJCAAI; ISSN: 0007-0920

PB Nature Publishing Group

DT Journal

LA English

AB The ID1 protein, an inhibitor of basic helix-loop-helix transcription

factors, has been involved in multiple cellular processes including cell

cycle regulation, apoptosis, and angiogenesis. To evaluate the importance

of ID1 in malignant melanoma, tumor cell expression was examined by

immunohistochem. in 119 cases of nodular melanoma using tissue microarray

technique, and related to multiple tumor markers including proliferation,

p16 expression, angiogenesis and patient survival. Strong ID1 expression

was significantly associated with increased tumor thickness, and significantly reduced survival. Also, increased ID1 was associated with loss

of thrombospondin-1 (TSP-1) expression, a known inhibitor of angiogenesis,

and increased intensity of ephrin-A1 and its receptor EPHA2. Presence of

BRAF mutations was related to strong ID1 expression, but there was no

relationship with p16 protein expression. Further, no significant

correlation was found between ID1 and microvessel d. In conclusion, our

study supports a significant role of the ID1 protein in melanoma progression and patient prognosis. The absence of correlation with p16

protein expression and angiogenesis suggests that other regulatory

pathways and mechanisms might be influenced by ID1 in melanomas.

An

inverse relation between ID1 and TSP-1 expression support an important

role of ID1 in the regulation of this complex multitarget protein.

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:308529 CAPLUS  
DN 140:333599

TI Gene expression profile of human and mouse genes in atopic dermatitis and psoriasis patients and its use for diagnosis, therapy, and drug screening

IN Itoh, Mikito; Ogawa, Kaoru; Shinagawa, Akira; Sudo, Hajime; Ogawa,

Hideoki; Ra, Chisei; Mitsuishi, Kouichi

PA Genox Research, Inc., Japan; Juntendo University

SO PCT Int. Appl., 611 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
------	------------	------	------	-----------------

-----

-----  
PI WO 2004031386 A1 20040415 WO 2003-JP9808  
20030801

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,  
GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,  
LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,  
OM, PG,

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR,

TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY,  
EE, ES,  
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

SK, TR,  
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI,

TD, TG  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,

AU 2003252326 A1 20040423 AU 2003-252326  
20030801

PRAI JP 2002-229318 A 20020806

JP 2003-136543 A 20030514

WO 2003-JP9808 W 20030801

AB This invention provides gene expression profile between a rash site and a no-rash site in a patient with atopic dermatitis or a patient with psoriasis. The invention also provides gene expression profile between a

no-rash site in such a disease and a normal subject. Animal models,

particularly mouse for those diseases are also claimed. The gene expression profile provided in this invention can be used for diagnosis,

therapy, and drug screening for atopic dermatitis and psoriasis.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 MEDLINE on STN DUPLICATE 1

AN 2002707338 MEDLINE

DN PubMed ID: 12467573

TI Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases

from nanovolume crystallography.

AU Nowakowski Jacek; Cronin Ciaran N; McRee Duncan E; Knuth Mark W; Nelson

Christian G; Pavletich Nikola P; Rogers Joe; Sang Bi-Ching; Scheibe Daniel

N; Swanson Ronald V; Thompson Devon A

CS Syrrx, Inc., 10410 Science Center Drive, San Diego, CA 92121, USA..

jacek.nowakoski@syrrx.com

SO Structure (Cambridge, Mass. : 2001), (2002 Dec) Vol. 10, No. 12, pp.

1659-67.

Journal code: 101087697. ISSN: 0969-2126.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

OS PDB-1MP8; PDB-1MQ4; PDB-1MQB

EM 200305

ED Entered STN: 20021217

Last Updated on STN: 20030529

Entered Medline: 20030528

AB Protein kinases are important drug targets in human cancers, inflammation, and metabolic diseases. This report presents the structures of kinase

domains for three cancer-associated protein kinases: ephrin receptor A2

(EphA2), focal adhesion kinase (FAK), and Aurora-A. The expression profiles of EphA2, FAK, and Aurora-A in carcinomas suggest that inhibitors of these kinases may have inherent potential as therapeutic agents. The structures were

determined from crystals grown in nanovolume droplets, which produced

high-resolution diffraction data at 1.7, 1.9, and 2.3 Å for FAK, Aurora-A,

and EphA2, respectively. The FAK and Aurora-A structures are the first

determined within two unique subfamilies of human kinases, and all three structures provide new insights into kinase regulation and the design of selective inhibitors.

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2	EphA2 near4 expression	USPAT	OR	OFF	2006/02/27:20:17



A service of the National Library of Medicine  
and the National Institutes of Health

My NCBI

[Sign In] [Register]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books  
Search [PubMed] [Go] [Clear]

Limits Preview/Index History Clipboard Details

Display **Summary** Show 20 Sort by Send to

All: 5 Review: 0

Items 1 - 5 of 5

One page.

1: [McLaughlin T, O'Leary DD.](#) Related Articles, Links  
 Functional consequences of coincident expression of EphA receptors and ephrin-A ligands.  
*Neuron.* 1999 Apr;22(4):636-9. No abstract available.  
 PMID: 10230779 [PubMed - indexed for MEDLINE]

2: [Chen J, Ruley HE.](#) Related Articles, Links  
 An enhancer element in the EphA2 (Eck) gene sufficient for rhombomere-specific expression is activated by HOXA1 and HOXB1 homeobox proteins.  
*J Biol Chem.* 1998 Sep 18;273(38):24670-5.  
 PMID: 9733765 [PubMed - indexed for MEDLINE]

3: [Kikawa KD, Vidale DR, Van Etten RL, Kinch MS.](#) Related Articles, Links  
 Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation.  
*J Biol Chem.* 2002 Oct 18;277(42):39274-9. Epub 2002 Aug 6.  
 PMID: 12167657 [PubMed - indexed for MEDLINE]

4: [Zelinski DP, Zantek ND, Walker-Daniels J, Peters MA, Taparowsky EJ, Kinch MS.](#) Related Articles, Links  
 Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase.  
*J Cell Biochem.* 2002;85(4):714-20.  
 PMID: 11968011 [PubMed - indexed for MEDLINE]

5: [Dohn M, Jiang J, Chen X.](#) Related Articles, Links  
 Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis.  
*Oncogene.* 2001 Oct 4;20(45):6503-15.  
 PMID: 11641774 [PubMed - indexed for MEDLINE]

Display **Summary** Show 20 Sort by Send to

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623SQS

**PASSWORD :**

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available  
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE  
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of  
TOXCENTER  
NEWS 6 DEC 14 CA/CAplus to be enhanced with updated IPC codes  
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAplus  
with the  
NEWS 8 DEC 23 IPC reform  
USPATFULL/  
NEWS 9 JAN 13 New IPC8 SEARCH, DISPLAY, and SELECT fields in  
NEWS 10 JAN 13 USPAT2  
JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB  
added to New IPC 8 SEARCH, DISPLAY, and SELECT enhancements  
NEWS 11 JAN 17 INPADOC  
NEWS 12 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 13 JAN 30 IPC 8 in the WPI family of databases including WPIFV  
NEWS 14 JAN 31 Saved answer limit increased  
Monthly current-awareness alert (SDI) frequency  
added to TULSA  
NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN  
AnaVist  
NEWS 16 FEB 22 visualization results  
NEWS 17 FEB 22 Status of current WO (PCT) information on STN  
databases on STN  
NEWS 18 FEB 22 The IPC thesaurus added to additional patent  
Updates in EPFULL; IPC 8 enhancements added  
NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a

AT

<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* STN Columbus \*

FILE 'HOME' ENTERED AT 19:40:58 ON 27 FEB 2006

=> File Medline EMBASE Biosis Caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION

FILE 'MEDLINE' ENTERED AT 19:41:07 ON 27 FEB 2006

FILE 'EMBASE' ENTERED AT 19:41:07 ON 27 FEB 2006  
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 19:41:07 ON 27 FEB 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 19:41:07 ON 27 FEB 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> S BMS-A  
L1 24 BMS-A

=> s 12 (4A) kinase  
L2 NOT FOUND

The L-number entered could not be found. To see the definition of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s 11 (4A) kinase  
L2 4 L1 (4A) KINASE

=> duplicate

ENTER REMOVE, IDENTIFY, ONLY, OR (?) :remove  
ENTER L# LIST OR (END) :l1  
DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, BIOSIS, CAPLUS'  
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N) :n  
PROCESSING COMPLETED FOR L1  
L3 18 DUPLICATE REMOVE L1 (6 DUPLICATES REMOVED)

=> s 13 (4A) kinase  
L4 4 L3 (4A) KINASE

=> d 14 1-4 bib ab

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:120539 CAPLUS  
DN 144:164210  
TI Gene expression biomarkers for predicting activity of compounds  
that  
interact with protein tyrosine kinases and pathways in breast  
cells  
IN Huang, Fei; Han, Xia; Reeves, Karen A.; Amler, Lukas C.;  
Fairchild, Craig  
R.; Lee, Francis Y.; Shaw, Peter  
PA USA  
SO U.S. Pat. Appl. Publ., 74 pp., Cont.-in-part of U.S. Ser. No.  
648,593.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 2

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
-----	-----	----	-----	-----
-----	-----	-----	-----	-----
PI 20050304	US 2006029944	A1	20060209	US 2005-72175
20030826	US 2004106132	A1	20040603	US 2003-648593
PRAI	US 2002-406385P	P	20020827	
	US 2003-648593	A2	20030826	
AB	The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., breast cell lines, to treatment with compds. that interact with and modulate, e.g., inhibit, protein tyrosine kinases. The protein tyrosine kinase inhibitor compound <b>BMS-A</b> was tested for cytotoxicity in vitro against a panel of 23 human breast cell lines. Expression profiling data of 44,792 probe sets represented on the Affymetrix HG-U133 array set were obtained for the 23 untreated breast			

cell lines. One hundred thirty-seven genes are identified whose expression is correlated with sensitivity/resistance of the cell lines and

IC50 values. These polynucleotides have been shown, through a weighted

voting cross-validation program, to have utility in predicting the

resistance and sensitivity of breast cell lines to **BMS-A** and other protein tyrosine kinase inhibitor compds. The expression level or phosphorylation status of some polynucleotides is

regulated by treatment with a particular protein tyrosine kinase inhibitor

compound, thus indicating that these polynucleotides are involved in the

protein tyrosine kinase signal transduction pathway. Such polynucleotides, whose expression levels correlate highly with drug

sensitivity or resistance and which are modulated by treatment with the

compds., comprise polynucleotide predictor or marker sets useful in

methods of predicting drug response, and as prognostic or diagnostic

indicators in disease management.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:29606 CAPLUS

DN 144:121754

TI Gene expression profile for predicting activity of compounds that interact

with and/or modulate protein tyrosine kinases and/or protein tyrosine

pathways in lung cancer cells

IN Huang, Fei; Reeves, Karen A.; Han, Xia; Fairchild, Craig R.; Shaw, Peter

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 130 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.
DATE	-----	-----	-----

PI WO 2006005035 A2 20060112 WO 2005-US23687  
20050629

CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,

KR, KZ, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP,  
MZ, NA, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
SG, SK, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
VN, YU, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,  
HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,  
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM

US 2006019284 A1 20060126 US 2005-169041

20050628

PRAI US 2004-584405P P 20040630

AB The present invention describes polynucleotides that have been discovered

to correlate to the relative intrinsic sensitivity or resistance of cells,

e.g., lung cell lines, to treatment with compds. that interact with and

modulate, e.g., inhibit, protein tyrosine kinases, such as, for example,

members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes,

Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Ephr. These polynucleotides

have been shown, through a weighted voting cross validation program, to

have utility in predicting the resistance and sensitivity of lung cell

lines to the compds. The expression level of some polynucleotides is

regulated by treatment with a particular protein tyrosine kinase inhibitor

compound, thus indicating that these polynucleotides are involved in the

protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine

kinase. The Affymetrix human HG-U133 GeneChip set of over 44,792 probe

sets was used to identify 129 polynucleotides that are highly correlated

with a resistance/sensitivity phenotype classification of 23 lung cell

lines subjected to treatment with the protein tyrosine kinase inhibitor compound **BMS-A**. Of the 129 predictor polynucleotides, 81 polynucleotides highly expressed in the cell lines were classified as sensitive to BMS-A, while 48 polynucleotides highly expressed in the cell lines were classified as resistant to BMS-A. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compds., comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., lung cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:203933 CAPLUS  
DN 140:247003  
TI Expressed polynucleotides markers for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells  
IN Huang, Fei; Han, Xia; Reeves, Karen A.; Amler, Lucas; Fairchild, Craig R.; Lee, Francis Y.; Shaw, Peter  
PA Bristol-Myers Squibb Company, USA  
SO PCT Int. Appl., 649 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
-----	-----	-----	-----	-----
-----	-----	-----	-----	-----
PI WO 2004020583 20030826	A2	20040311	WO 2003-US26491	
WO 2004020583	C1	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

LK, LR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
NZ, OM, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,  
TM, TN, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI,  
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
TD, TG

EP 1572957 A2 20050914 EP 2003-770252  
20030826

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,  
MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU,  
SK

PRAI US 2002-406385P P 20020827  
WO 2003-US26491 W 20030826

AB The present invention describes polynucleotides that have been discovered

to correlate to the relative intrinsic sensitivity or resistance of cells

(e.g., breast cell lines) to treatment with compds. that interact with and

modulate (e.g., inhibit) protein tyrosine kinases, such as, for example,

members of the Src family of tyrosine kinases (e.g., Src, Fgr, Fyn, Yes,

Blk, Hck, Lck and Lyn), as well as other protein tyrosine kinases,

including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and

sensitivity of breast cell lines to the compds. Thus, 137 polynucleotides

are provided that highly correlate with a resistance/sensitivity phenotype

classification of 23 breast cell lines for the protein tyrosine kinase inhibitor **BMS-A**. The expression level or phosphorylation status of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus

indicating that these polynucleotides are involved in the protein tyrosine

kinase signal transduction pathway. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and

which are modulated by treatment with the compds., comprise polynucleotide

predictor or marker sets useful in methods of predicting drug response,

and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., breast cancer, in which

signaling through the protein tyrosine kinase pathway is involved with the disease process.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:591309 CAPLUS

DN 139:128005

TI Polynucleotides and polypeptides useful in screening compounds interacting

with protein tyrosine kinases and/or protein tyrosine kinase pathways in

drug-sensitive and drug-resistant colon cells

IN Huang, Fei; Fairchild, Craig R.; Lee, Francis Y.; Shaw, Peter

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

-----

-----

-----

-----

-----  
PI WO 2003062395 A2 20030731 WO 2003-US1981  
20030117  
WO 2003062395 A3 20050407  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
CH, CN,  
GE, GH,  
LK, LR,  
OM, PH,  
TT, TZ,  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY,  
EE, ES,  
TR, BF,  
TG

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,  
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR,  
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,

EP 1534739 A2 20050601 EP 2003-707494  
20030117 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,  
MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU,  
SK JP 2005523688 T2 20050811 JP 2003-562263  
20030117 PRAI US 2002-350061P P 20020118  
WO 2003-US1981 W 20030117  
AB The present invention describes polynucleotides and polypeptides  
that have  
been discovered to correlate to the relative intrinsic  
sensitivity or  
resistance of cells, e.g., colon cell lines, to treatment with  
compds.  
that interact with and inhibit src tyrosine kinases. These  
polynucleotides and polypeptides have been shown, through a  
weighted  
voting cross-validation program, to have utility in predicting  
the  
intrinsic resistance and sensitivity of colon cell lines to  
these compds.  
Oligonucleotide microarrays (the Affymetrix HG-U95Av2 array)  
were utilized  
to measure the expression levels of >12,000 polynucleotides and  
polypeptides in a panel of 31 untreated colon cell lines for  
which the  
drug sensitivity to four src kinase inhibitor compds. (BMS-A, BMS-B, BMS-C, BMS-D) was determined using an in vitro  
cytotoxicity assay to determination IC50. Such polynucleotides  
and polypeptides  
whose expression levels correlate highly with drug sensitivity or  
resistance comprise predictor or marker sets of polynucleotides  
and  
polypeptides that are useful in methods of predicting drug  
response and as  
prognostic or diagnostic indicators in disease management,  
particularly in  
those disease areas in which signaling through src tyrosine  
kinase of the  
src tyrosine kinase pathway is involved with the disease process.

=> S L3 NOT L4  
L5 14 L3 NOT L4

=> d 15 1-14 bib

L5 ANSWER 1 OF 14 MEDLINE on STN  
AN 2004135848 MEDLINE  
DN PubMed ID: 15028375

TI The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS).  
AU Schampaert Erick; Cohen Eric A; Schluter Michael; Reeves Francois; Traboulsi Mouhieddin; Title Lawrence M; Kuntz Richard E; Popma Jeffrey J  
CS Hopital du Sacre-Coeur de Montreal, 5400 Bl. Gouin O., Montreal, Quebec, Canada H4J 1C5. (C-SIRIUS Investigators).  
erick.schaempaert.hsc@ssss.gouv.qc.ca  
SO Journal of the American College of Cardiology, (2004 Mar 17)  
Vol. 43, No. 6, pp. 1110-5.  
Journal code: 8301365. ISSN: 0735-1097.  
CY United States  
DT (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(MULTICENTER STUDY)  
(RANDOMIZED CONTROLLED TRIAL)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 200404  
ED Entered STN: 20040319  
Last Updated on STN: 20040407  
Entered Medline: 20040406  
L5 ANSWER 2 OF 14 MEDLINE on STN  
AN 2002473559 MEDLINE  
DN PubMed ID: 12235503  
TI [Burning mouth].  
Mundbrennen.  
AU Witt E; Palla S  
CS Klinik fur Kaufunktionsstorungen und Totalprothetik, Zentrum fur Zahns-, Mund- und Kieferheilkunde, Universitat Zurich, Switzerland.  
SO Schmerz (Berlin, Germany), (2002 Sep) Vol. 16, No. 5, pp. 389-94. Ref: 67  
Journal code: 8906258. ISSN: 0932-433X.  
CY Germany: Germany, Federal Republic of  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
LA German  
FS Priority Journals  
EM 200212  
ED Entered STN: 20020918  
Last Updated on STN: 20021218  
Entered Medline: 20021213

L5 ANSWER 3 OF 14 MEDLINE on STN  
AN 1998371306 MEDLINE  
DN PubMed ID: 9706058  
TI Continuous blood withdrawal as a rapid screening method for determining clearance of oral bioavailability in rats.  
AU Humphreys W G; Obermeier M T; Morrison R A  
CS Department of Metabolism and Pharmacokinetics, Bristol-Meyers Squibb  
Pharmaceutical Research Institute, Princeton, New Jersey 08543,  
USA..  
humphrew@bms.com  
SO Pharmaceutical research, (1998 Aug) Vol. 15, No. 8, pp. 1257-61.

Journal code: 8406521. ISSN: 0724-8741.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199810  
ED Entered STN: 19981029  
Last Updated on STN: 19981029  
Entered Medline: 19981020

L5 ANSWER 4 OF 14 MEDLINE on STN  
AN 90000961 MEDLINE  
DN PubMed ID: 2789896  
TI Oral medicine in practice: burning mouth syndrome.  
AU Lamey P J; Lewis M A  
SO British dental journal, (1989 Sep 23) Vol. 167, No. 6, pp. 197-200.  
Journal code: 7513219. ISSN: 0007-0610.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Dental Journals; Priority Journals  
EM 198911  
ED Entered STN: 19900328  
Last Updated on STN: 19900328  
Entered Medline: 19891109

L5 ANSWER 5 OF 14 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN  
AN 2000259284 EMBASE  
TI [Conditions of selection of 'thymidine analogue mutations' (TAMs) in naive patients receiving different antiretroviral combinations including d4T].  
CONDITIONS DE SELECTION DES << THYMIDINES ANALOGUES MUTATIONS >> (TAMS)  
CHEZ DES PATIENTS NAIFS TRAITES PAR DIFFERENTES COMBINAISONS INCLUANT LA

D4T.

AU Mouroux M.; Izopet J.; Descamps D.; Delaugerre C.; Yvon-Groussin A.; Angleraud F.; Coutellier A.; Bonmarchand M.; Valantin M.A.; Matheron S.; Agut H.; Katlama C.; Brun-Vezinet F.; Calvez V.

CS M. Mouroux, Laboratoire de Virologie, Hopital Pitie-Salpetriere, 83, boulevard de l'Hopital, 75013 Paris, France

SO Pathologie Biologie, (2000) Vol. 48, No. 5, pp. 508-512. .

Refs: 14  
ISSN: 0369-8114 CODEN: PTBIAN

CY France

DT Journal; Conference Article

FS 004 Microbiology  
037 Drug Literature Index

LA French

SL English; French

ED Entered STN: 20000810  
Last Updated on STN: 20000810

L5 ANSWER 6 OF 14 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

AN 1999133274 EMBASE

TI [Psychopharmacological treatment of burning mouth syndrome (BMS). A study on a sample of 121 patients].  
TRATTAMENTO PSICOFARMACOLOGICO DELLA BURNING MOUTH SYNDROME (BMS)

STUDIO SU  
DI UN CAMPIONE DI 121 PAZIENTI.

AU Bogetto F.; Revello R.B.; Ferro G.; Maina G.; Ravizza L.

CS F. Bogetto, Clinica Psichiatrica, Via Cherasco, 11, 10126 Torino, Italy

SO Minerva Psichiatrica, (1999) Vol. 40, No. 1, pp. 1-10. .

Refs: 60  
ISSN: 0374-9320 CODEN: MPSIDG

CY Italy

DT Journal; Article

FS 032 Psychiatry  
037 Drug Literature Index

LA Italian

SL English; Italian

ED Entered STN: 19990510  
Last Updated on STN: 19990510

L5 ANSWER 7 OF 14 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

AN 97363002 EMBASE

DN 1997363002

TI Case study: Investigation into the subjective strain at two differently

designed automobile assembly workplaces.

AU Schutte M.; Schuder D.

CS M. Schutte, Institut fur Arbeitsphysiologie, Universitat Dortmund,  
Abteilung Ergonomie, Ardeystrasse 67, D-44139 Dortmund, Germany

SO International Journal of Industrial Ergonomics, (1997) Vol. 20,  
No. 5, pp. 413-422. .

Refs: 23

ISSN: 0169-8141 CODEN: IJIEES

PUI S 0169-8141(96)00091-1

CY Netherlands

DT Journal; Article

FS 035 Occupational Health and Industrial Medicine

LA English

SL English

ED Entered STN: 971212  
Last Updated on STN: 971212

L5 ANSWER 8 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 2005:190830 BIOSIS

DN PREV200500192696

TI Species and pH dependent enzyme hydrolysis: Importance of pH control  
during sample analysis.

AU Fura, Aberra [Reprint Author]; Vyas, Viral; Humphreys, W. Griffith

CS Pharmaceut Res InstDept Metab and Pharmacokinet, Bristol Myers Squibb Co,  
Princeton, NJ, 08534, USA

SO Drug Metabolism Reviews, (August 2004) Vol. 36, No. Suppl. 1,  
pp. 203.  
print.

Meeting Info.: 7th International Meeting of the International Society for  
the Study of Xenobiotics. Vancouver, BC, Canada. August 29-September 02,  
2004. International Society for the Study of Xenobiotics.

ISSN: 0360-2532 (ISSN print).

DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 25 May 2005  
Last Updated on STN: 25 May 2005

L5 ANSWER 9 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 2003:278321 BIOSIS

DN PREV200300278321

TI Activity of BMS284-756 against Streptococcus pneumoniae and viridans group

streptococci.

AU Houssaye, S. [Reprint Author]; Gutmann, L. [Reprint Author];  
Varon, E.  
[Reprint Author]

CS Centre National de Reference des Pneumocoques, Hopital European  
G.  
Pompidou, Paris, France

SO Abstracts of the Interscience Conference on Antimicrobial Agents  
and  
Chemotherapy, (2002) Vol. 42, pp. 153. print.  
Meeting Info.: 42nd Interscience Conference on Antimicrobial  
Agents and  
Chemotherapy. San Diego, CA, USA. September 27-30, 2002.

American Society  
for Microbiology.

DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 11 Jun 2003  
Last Updated on STN: 11 Jun 2003

L5 ANSWER 10 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson  
Corporation on  
STN

AN 2001:320612 BIOSIS

DN PREV200100320612

TI Butterfly numbers and weather: Predicting historical trends in  
abundance  
and the future effects of climate change.

AU Roy, D. B. [Reprint author]; Rothery, P.; Moss, D.; Pollard, E.;  
Thomas,  
J. A.

CS Centre for Ecology and Hydrology, Monks Wood, Abbots Ripton,  
Huntingdon,  
Cambridgeshire, PE28 2LS, UK  
dbr@ceh.ac.uk

SO Journal of Animal Ecology, (March, 2001) Vol. 70, No. 2, pp.  
201-217.  
print.  
CODEN: JAECAP. ISSN: 0021-8790.

DT Article

LA English

ED Entered STN: 4 Jul 2001  
Last Updated on STN: 19 Feb 2002

L5 ANSWER 11 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson  
Corporation on  
STN

AN 2000:536953 BIOSIS

DN PREV200000536953

TI Antimicrobial activity of BMS 284756 (BMS), a new  
desfluoroquinolone, tested against S. pneumoniae (SPN), H.  
influenzae

(HI), and *M. catarrhalis* (MCAT) isolates for SENTRY antimicrobial surveillance program (Latin America, 1999).

AU Gales, A. C. [Reprint author]; Sader, H. S.; Jones, R. N.  
[Reprint author]

CS Univ. of Iowa Coll. of Med., Iowa City, IA, USA

SO Abstracts of the Interscience Conference on Antimicrobial Agents and

Chemotherapy, (2000) Vol. 40, pp. 173. print.

Meeting Info.: 40th Interscience Conference on Antimicrobial Agents and

Chemotherapy. Toronto, Ontario, Canada. September 17-20, 2000.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

Conference; (Meeting Poster)

LA English

ED Entered STN: 13 Dec 2000

Last Updated on STN: 11 Jan 2002

L5 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:697737 CAPLUS

DN 137:385316

TI The apparent activation energy and relaxation volume from the point of

view of Adam-Gibbs theory

AU Solunov, Christo Al

CS University of Plovdiv "P Hilendarsky", Plovdiv, 4000, Bulg.

SO Journal of Physics: Condensed Matter (2002), 14(31), 7297-7309  
CODEN: JCOMEL; ISSN: 0953-8984

PB Institute of Physics Publishing

DT Journal

LA English

RE.CNT 90 THERE ARE 90 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:293593 CAPLUS

DN 136:319398

TI Selective maxi-K-potassium channel openers functional under conditions of

high intracellular calcium concentration, methods and uses thereof

IN Gribkoff, Valentin K.; Post-Munson, Debra J.; Yeola, Sarita W.; Boissard,

Christopher G.; Hewawasam, Piyasena

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.
DATE			

-----

PI WO 2002030868 A1 20020418 WO 2001-US32079  
 20011012

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
 CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,  
 GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,  
 PH, PL,  
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,  
 UA, UG,  
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE,  
 CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,  
 TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
 TG

CA 2425771 AA 20020418 CA 2001-2425771  
 20011012

US 2002045566 A1 20020418 US 2001-975881  
 20011012

AU 2002013204 A5 20020422 AU 2002-13204  
 20011012

EP 1330426 A1 20030730 EP 2001-981570  
 20011012

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,  
 MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 JP 2004511457 T2 20040415 JP 2002-534257  
 20011012

US 2005043293 A1 20050224 US 2004-952523  
 20040928

PRAI US 2000-240146P P 20001013  
 US 2001-975881 A3 20011012  
 WO 2001-US32079 W 20011012

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1980:31984 CAPLUS  
 DN 92:31984  
 TI Thermal fixing type toners  
 IN Watanabe, Shotaro; Tozawa, Katsutoshi; Uetake, Shigeru  
 PA Konishiroku Photo Industry Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 7 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.
DATE			
-----	-----	-----	-----
PI JP 54048556 19770714	A2	19790417	JP 1977-83567
JP 58045022	B4	19831006	
PRAI JP 1977-83567	A	19770714	



A service of the National Library of Medicine  
and the National Institutes of Health

My NCBI  
[Sign In] [Register]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books  
Search  for

Display  Show  Sort by  Send to

All: 5 Review: 1

Items 1 - 5 of 5

One page.

About Entrez  
NCBI Toolbar

Text Version

Entrez PubMed  
Overview  
Help | FAQ  
Tutorials  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
Special Queries  
LinkOut  
My NCBI

Related Resources  
Order Documents  
NLM Mobile  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

1: [Straume O, Akslen LA.](#)

Related Articles, Links

Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma.  
*Br J Cancer.* 2005 Oct 17;93(8):933-8.  
PMID: 16189525 [PubMed - indexed for MEDLINE]

2: [Xu H, Tian W, Lindsley JN, Ovama TT, Capasso JM, Rivard CJ, Cohen HT, Bagnasco SM, Anderson S, Cohen DM.](#)

Related Articles, Links

EphA2: expression in the renal medulla and regulation by hypertonicity and urea stress in vitro and in vivo.  
*Am J Physiol Renal Physiol.* 2005 Apr;288(4):F855-66. Epub 2004 Nov 23.  
PMID: 15561974 [PubMed - indexed for MEDLINE]

3: [Cheng Q, Sasaki Y, Shoji M, Sugiyama Y, Tanaka H, Nakayama T, Mizuki N, Nakamura F, Takei K, Goshima Y.](#)

Related Articles, Links

Cdk5/p35 and Rho-kinase mediate ephrin-A5-induced signaling in retinal ganglion cells.  
*Mol Cell Neurosci.* 2003 Nov;24(3):632-45.  
PMID: 14664814 [PubMed - indexed for MEDLINE]

4: [Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V, Seftor RE.](#)

Related Articles, Links

Remodeling of the microenvironment by aggressive melanoma tumor cells.  
*Ann N Y Acad Sci.* 2003 May;995:151-61. Review.  
PMID: 12814947 [PubMed - indexed for MEDLINE]

5: [D'Antico TA, Aloia TA, Moore MB, Coulou DII, Hendrix JE 2nd, Kitch MS, Harpelle DH Jr.](#)

Related Articles, Links

Predicting the sites of metastases from lung cancer using molecular biologic markers.  
*Ann Thorac Surg.* 2001 Oct;72(4):1144-8.  
PMID: 11603427 [PubMed - indexed for MEDLINE]

Display  Show  Sort by  Send to


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Feb 13 2006 06:29:17



A service of the National Library of Medicine  
and the National Institutes of Health

My NCBI [Sign In] [Register]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search

for **EphA2 expression kinase inhibitor**

Display

All: 1 Review: 0

1: Xu H, Tian W, Lindsley JN, Oyama TT, Capasso JM, Rivard CJ, Cohen HT, Bagnasco SM, Anderson S, Cohen DM. [Related Articles](#), [Links](#)

EphA2: expression in the renal medulla and regulation by hypertonicity and urea stress in vitro and in vivo. [Am J Physiol Renal Physiol. 2005 Apr;288\(4\):F855-66. Epub 2004 Nov 23.](#)  
PMID: 15561974 [PubMed - indexed for MEDLINE]

About Entrez  
NCBI Toolbar

[Text Version](#)

Entrez PubMed  
Overview  
Help | FAQ  
Tutorials  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
Special Queries  
LinkOut  
My NCBI

Related Resources  
Order Documents  
NLM Mobile  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
[ClinicalTrials.gov](#)  
PubMed Central

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Feb 13 2006 12:53:38